GlassScriptPhysician profile
Smitha K Thomas Mathew
NPI 1881824613
$2,506.28
in general payments reported to CMS, 2019-2025
19 companies · $37.92 in 2025
The $37.92 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $145 · 2021: $747 · 2022: $837 · 2023: $203 · 2024: $310 · 2025: $37.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $617.19 | 2019-2023 | Lokelma |
| Janssen Pharmaceuticals, INC | $321.22 | 2021-2022 | |
| Vifor Pharma, INC. | $312.70 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.12 | 2021-2024 | |
| Akebia Therapeutics INC | $211.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.86 | 2019-2022 | |
| Ardelyx, INC. | $121.26 | 2024 | Xphozah 30 Mg, Ibsrela |
| Outset Medical INC | $88.59 | 2024 | |
| Amgen INC. | $83.02 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $80.28 | 2022 | |
| Alexion Pharmaceuticals, INC. | $70.68 | 2021-2024 | Strensiq, Ultomiris |
| Glaxosmithkline, LLC. | $58.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.63 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $29.39 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.42 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26.59 | 2023 | Minimed 780g |
| Travere Therapeutics, INC. | $20.36 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2025 | Caldolor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Thomas Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.